



Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis

Brooke Levis,¹ Andrea Benedetti,² Brett D Thombs,¹ on behalf of the DEPRESsion Screening Data (DEPRESSD) Collaboration

¹Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University, Montréal, Québec, Canada

²Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada

Correspondence to: B D Thombs
brett.thombs@mcgill.ca

(ORCID 0000-0002-5644-8432)

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2019;365:l1476
<http://dx.doi.org/10.1136/bmj.l1476>

Accepted: 13 March 2019

ABSTRACT

OBJECTIVE

To determine the accuracy of the Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression.

DESIGN

Individual participant data meta-analysis.

DATA SOURCES

Medline, Medline In-Process and Other Non-Indexed Citations, PsycINFO, and Web of Science (January 2000-February 2015).

INCLUSION CRITERIA

Eligible studies compared PHQ-9 scores with major depression diagnoses from validated diagnostic interviews. Primary study data and study level data extracted from primary reports were synthesized. For PHQ-9 cut-off scores 5-15, bivariate random effects meta-analysis was used to estimate pooled sensitivity and specificity, separately, among studies that used semistructured diagnostic interviews, which are designed for administration by clinicians; fully structured interviews, which are designed for lay administration; and the Mini International Neuropsychiatric (MINI) diagnostic interviews, a brief fully structured interview. Sensitivity and specificity were examined among participant subgroups and, separately, using meta-regression, considering all subgroup variables in a single model.

RESULTS

Data were obtained for 58 of 72 eligible studies (total n=17 357; major depression cases n=2312). Combined sensitivity and specificity was maximized at a cut-off score of 10 or above among studies using a semistructured interview (29 studies, 6725 participants; sensitivity 0.88, 95% confidence interval 0.83 to 0.92; specificity 0.85, 0.82 to 0.88). Across cut-off scores 5-15, sensitivity with semistructured interviews was 5-22% higher than for fully structured interviews (MINI excluded; 14 studies, 7680 participants) and 2-15% higher than for the MINI (15 studies, 2952 participants). Specificity was similar across diagnostic interviews. The PHQ-9 seems to be similarly sensitive but may be less specific for younger patients than for older patients; a cut-off score of 10 or above can be used regardless of age..

CONCLUSIONS

PHQ-9 sensitivity compared with semistructured diagnostic interviews was greater than in previous conventional meta-analyses that combined reference standards. A cut-off score of 10 or above maximized combined sensitivity and specificity overall and for subgroups.

REGISTRATION

PROSPERO CRD42014010673.

Introduction

Screening for depression refers to the use of a depression screening questionnaire to identify patients who may have depression but have not been identified. When screening programs are recommended, clinicians are advised to administer a depression symptom questionnaire and to use a pre-identified cut-off threshold to classify patients as having positive or negative screening results. Those with positive screening results can then be evaluated to determine whether they have depression and, if appropriate, should be offered treatment.^{1 2}

The Patient Health Questionnaire-9 (PHQ-9) is a nine item questionnaire designed to screen for depression in primary care and other medical settings.³⁻⁷ The standard cut-off score for screening to identify possible major depression is 10 or above,³⁻⁷ which was established in the first study on the PHQ-9 (total n=580, major depression n=41).^{3 5}

A conventional PHQ-9 meta-analysis from 2015 (36 studies, 21 292 participants) evaluated sensitivity and specificity for cut-off scores 7-15 by combining accuracy results for each cut-off score that were published in included primary studies.⁸ Pooled

WHAT IS ALREADY KNOWN ON THIS TOPIC

The Patient Health Questionnaire-9 (PHQ-9) is the most commonly used tool for screening for depression in primary care

Previous meta-analyses on diagnostic test accuracy of PHQ-9 have had limitations including selective cut-off reporting in primary studies and inability to assess differences across patient subgroups

They also did not exclude participants already diagnosed as having or being treated for depression, who would not be screened in practice

WHAT THIS STUDY ADDS

Diagnostic accuracy of PHQ-9 compared with diagnoses made by semistructured diagnostic interviews is greater than when compared with diagnoses made by other reference standards

Diagnostic accuracy of PHQ-9 does not differ substantively across participant subgroups except for age, where it may be more specific among older patients

The standard cut-off score of 10 or greater maximizes combined sensitivity and specificity overall and for subgroups

A web based tool is available to estimate the expected number of positive screens and true and false screening outcomes based on study results (depressionscreening100.com/phq)

sensitivity for the standard cut-off score of 10 was 0.78 (95% confidence interval 0.70 to 0.84), and pooled specificity was 0.87 (0.84 to 0.90). Incomplete reporting of results from cut-off scores other than 10 in the primary studies that were included, however, resulted in cut-off score ranges in which sensitivity implausibly increased as cut-off scores increased.⁸ This suggested possible selective cut-off reporting in some primary studies to maximize accuracy.^{8,9} Additional limitations included the inability to assess differences across patient subgroups, as subgroup results were not reported in primary studies; the inability to exclude participants already diagnosed as having or being treated for depression, who would not be screened in practice but were included in many primary studies^{10,11}; and the combining of accuracy estimates without differentiating between reference standards.¹² Semistructured diagnostic interviews (for example, Structured Clinical Interview for DSM Disorders (SCID)¹³) are intended to be used by experienced diagnosticians and require clinical judgment. Fully structured interviews (for example, Composite International Diagnostic Interview (CIDI)¹⁴) are fully scripted and designed to be administered by lay interviewers to reduce the cost of employing trained clinical interviewers; they are intended to achieve a high level of standardization but may sacrifice accuracy.¹⁵⁻¹⁸ The Mini International Neuropsychiatric Interview (MINI) is fully structured but was designed for very rapid administration and described by its authors as being overinclusive as a result.^{19,20} In a recent analysis, controlling for depressive symptom scores, we found that the MINI classified approximately twice as many participants as having major depression as other fully structured interviews. Compared with semistructured interviews, fully structured interviews (MINI excluded) classified more patients with low symptom scores but fewer patients with high symptom scores as having major depression.¹²

Individual participant data meta-analysis involves a standard systematic review, then synthesis of participant level data from primary studies rather than summary results from study reports.²¹ Advantages include the ability to do subgroup analyses not reported in primary studies, the ability to report results from all relevant cut-off scores from all included studies, and the ability to exclude participants already diagnosed as having or treated for depression who would not be screened in practice.

The objectives of this study were to use individual participant data meta-analysis to evaluate the diagnostic accuracy of the PHQ-9 screening tool among studies using semistructured, fully structured (MINI excluded), and MINI diagnostic interviews as reference standards, separately, with priority given to semistructured interview results; among participants not diagnosed as having or receiving treatment for a mental health problem; and among participant subgroups based on age, sex, country human development index, and recruitment setting.

Methods

This individual participant data meta-analysis was registered in PROSPERO (CRD42014010673), a protocol was published,²² and results were reported following PRISMA-DTA and PRISMA-IPD reporting guidelines.^{23,24}

Search strategy

A medical librarian searched Medline, Medline In-Process and Other Non-Indexed Citations via Ovid, PsycINFO, and Web of Science (January 1, 2000-February 7, 2015) on February 7, 2015, using a peer reviewed search strategy (supplementary methods A).²⁵ The search was limited to 2000 forward because the PHQ-9 was published in 2001.³ We also reviewed reference lists of relevant reviews and queried contributing authors about non-published studies. Search results were uploaded into RefWorks (RefWorks-COS, Bethesda, MD, USA). After de-duplication, unique citations were uploaded into DistillerSR (Evidence Partners, Ottawa, Canada) for storing and tracking of search results.

Identification of eligible studies

Datasets from articles in any language were eligible for inclusion if they included diagnostic classification for current major depressive disorder or major depressive episode on the basis of a validated semistructured or fully structured interview conducted within two weeks of PHQ-9 administration among participants aged 18 years or over who were not recruited from youth or psychiatric settings or because they were identified as having symptoms of depression. We required the diagnostic interviews and PHQ-9 to be administered within two weeks of each other because the *Diagnostic and Statistical Manual of Mental Disorders* (DSM) and international classification of diseases (ICD) diagnostic criteria for major depression specify that symptoms must have been present in the previous two weeks. We excluded patients from psychiatric settings and those already identified as having symptoms of depression because screening is done to identify previously unrecognized cases.

Datasets in which not all participants were eligible were included if primary data allowed selection of eligible participants. For defining major depression, we considered major depressive disorder or major depressive episode based on the DSM or ICD criteria. If more than one was reported, we prioritized major depressive episode over major depressive disorder, as screening would attempt to detect depressive episodes and further interview would determine whether the episode was related to major depressive disorder or bipolar disorder, and DSM over ICD. Across all studies, there were 23 discordant diagnoses depending on classification prioritization (0.1% of participants).

Two investigators independently reviewed titles and abstracts for eligibility. If either deemed a study potentially eligible, two investigators did full text review independently, with disagreements resolved by consensus, consulting a third investigator when

necessary. We consulted translators for languages other than those in which team members were fluent.

Data extraction, contribution, and synthesis

We invited authors of eligible datasets to contribute de-identified primary data. Two investigators independently extracted country, recruitment setting (non-medical, primary care, inpatient specialty, outpatient specialty), and diagnostic interview from published reports, with disagreements resolved by consensus. We categorized countries as “very high,” “high,” or “low-medium” development on the basis of the United Nations’ human development index.²⁶ Participant level data included age, sex, major depression status, current mental health diagnosis or treatment, and PHQ-9 scores. In two primary studies, multiple recruitment settings were included, so recruitment setting was coded at the participant level. When datasets included statistical weights to reflect sampling procedures, we used the weights provided. For studies in which sampling procedures merited weighting but the original study did not weight, we constructed weights by using inverse selection probabilities. Weighting occurred, for instance, when a diagnostic interview was administered to all participants with positive screens and a random subset of participants with negative screens.

We converted individual participant data to a standard format and synthesized them into a single dataset with study level data. We compared published participant characteristics and diagnostic accuracy results with results from raw datasets and resolved any discrepancies in consultation with the original investigators.

Two investigators assessed risk of bias of included studies independently, on the basis of the primary publications, using the Quality Assessment of Diagnostic Accuracy Studies-2 tool (supplementary methods B).²⁷ Discrepancies were resolved by consensus.

Statistical analyses

We did three main sets of analyses. Firstly, we estimated sensitivity and specificity across PHQ-9 cut-off scores 5-15 for studies with semistructured (SCID,¹³ Schedules for Clinical Assessment in Neuropsychiatry,²⁸ Depression Interview and Structured Hamilton²⁹), fully structured (MINI excluded; CIDI,¹⁴ Clinical Interview Schedule-Revised,³⁰ Diagnostic Interview Schedule³¹), and MINI^{19 20} reference standards, separately. Secondly, for each reference standard category, we estimated sensitivity and specificity across PHQ-9 cut-off scores for all participants from primary studies, as has been done in existing conventional meta-analyses and, separately, among only participants who could be confirmed as not diagnosed as having or receiving treatment for a mental health problem at the time of assessment. We did this because existing conventional meta-analyses have all been based on primary studies that generally do not exclude patients already diagnosed as having or receiving treatment

for a mental health problem. As screening is done to identify previously unrecognized cases, those patients would not be screened in practice, and their inclusion in diagnostic accuracy studies could bias results.^{10 11} Thirdly, for each reference standard category, we estimated and compared sensitivity and specificity across PHQ-9 cut-off scores among subgroups based on age (<60 v ≥60 years), sex, country human development index (very high, high, low-medium), and recruitment setting (non-medical, primary, inpatient specialty, outpatient specialty). Among studies that used the MINI, we combined inpatient and outpatient specialty care settings, as only one study included inpatient participants. In each subgroup analysis, we excluded primary studies with no major depression cases, as this did not allow application of the bivariate random effects model. This resulted in a maximum of 15 participants excluded from any subgroup analysis.

For each meta-analysis, for cut-off scores 5-15 separately, bivariate random effects models were fitted via Gauss-Hermite adaptive quadrature.³² This two stage meta-analytic approach models sensitivity and specificity simultaneously, accounting for the inherent correlation between them and for precision of estimates within studies. For each analysis, this model provided estimates of pooled sensitivity and specificity.

To compare results across reference standards and other subgroups, we constructed empirical receiver operating characteristic curves for each group based on the pooled sensitivity and specificity estimates and calculated areas under the curve. We estimated differences in sensitivity and specificity between subgroups at each cut-off score by constructing confidence intervals for differences via the cluster bootstrap approach,^{33 34} resampling at study and participant levels. For each comparison, we ran 1000 iterations of the bootstrap. We removed iterations that did not produce difference estimates for cut-off scores 5-15 before determining confidence intervals and noted the number of iterations removed.

In addition to categorical subgroup analyses, we compared sensitivity and specificity across the different reference standards by doing one stage meta-regressions with interactions between reference standard category (reference category=semistructured interviews) and accuracy coefficients (logit(sensitivity) and logit(specificity)), and we compared results with those seen in the original two stage bivariate random effects meta-analytic models. Additionally, within each reference standard category, we did one stage meta-regressions in which we interacted all subgrouping variables (age (measured continuously), sex (reference category=women), country human development index (reference category=very high), and participant recruitment setting (reference category=primary care)) with logit(sensitivity) and logit(specificity). Similarly to our main subgroup analyses, we again determined which significant interactions replicated across all three reference standard categories. For subgrouping variables that were significantly associated with sensitivity or specificity coefficients for all three reference standard

categories for all or most cut-off scores in the main one stage meta-regression, we did additional one stage meta-regression to produce accuracy estimates for the subgroups of interest, and we compared these results with those seen in the original two stage bivariate random effects meta-analytic models. Although age was included as a continuous variable in the main meta-regression, we again dichotomized it (<60 v ≥60 years) to estimate accuracy and for comparison with the bivariate model results.

To investigate heterogeneity, we generated forest plots of sensitivities and specificities for cut-off score 10 for each study, first for all studies in each reference standard category and then separately across participant subgroups within each reference standard category. We quantified cut-off score 10 heterogeneity overall and across subgroups by reporting estimated variances of the random effects for sensitivity and specificity (τ^2) and estimating I^2 , the ratio of the estimated standard deviation of the pooled sensitivity (or specificity) from the random effects model to that from the corresponding fixed effects model.³⁵ We used a complete case analysis, as complete data for all subgrouping variables were available for 17 357 participants (98% of eligible participants in the database).

To estimate positive and negative predictive values using cut-off score 10 for different values of prevalence of major depression, we generated nomograms for each reference standard category by applying the cut-off 10 sensitivity and specificity estimates from the meta-analysis to hypothetical major depression prevalence values of 5-25%.

In sensitivity analyses, for each reference standard category, we compared accuracy results across subgroups based on Quality Assessment of Diagnostic Accuracy Studies-2 items for all items with at least 100 cases of major depression among participants categorized as having “low” risk of bias and among participants with “high” or “unclear” risk of bias.

We did not do sensitivity analyses that combined accuracy results from individual participant data meta-analysis with published results from studies that did not contribute individual participant data because among the 14 eligible studies that did not contribute individual participant data, only two studies with a

semistructured reference standard (total n=173, major depression n=29), one study with a fully structured reference standard (total n=730, major depression n=32), and one study using the MINI (total n=172, major depression n=33) published accuracy results eligible for this individual participant data meta-analysis. The other studies had eligible datasets but did not publish eligible diagnostic accuracy results (supplementary table A).

For all analyses, we used R (R version R 3.4.1 and R Studio version 1.0.143) using the `glmer` function within the `lme4` package, which uses one quadrature point. The only substantive deviations from our initial protocol were that we stratified accuracy results by reference standard category and did not do sensitivity analyses that combined accuracy results from individual participant data meta-analysis with published results from studies that did not contribute individual participant data.

Patient and public involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results

Search results and inclusion of primary datasets

Of 5248 unique titles and abstracts identified from the database search, 5039 were excluded after review of titles and abstracts and 113 after full text review, leaving 96 eligible articles with data from 69 unique participant samples, of which 55 (80%) contributed datasets (supplementary figure A). Reasons for exclusion for the 113 articles excluded at full text level are given in supplementary table A. In addition, authors of included studies contributed data from three unpublished studies, for a total of 58 datasets (total n=17 357, major depression n=2312 (13%)). Characteristics of included studies and eligible studies that did not provide datasets are shown in supplementary table B. Excluding the three

Table 1 | Participant data by diagnostic interview

Diagnostic interview	No of studies	No of participants	No (%) with major depression
Semistructured:			
SCID	26	4733	785 (17)
SCAN	2	1892	130 (7)
DISH	1	100	9 (9)
Fully structured:			
CIDI	11	6272	554 (9)
DIS	1	1006	221 (22)
CIS-R	2	402	64 (16)
MINI	15	2952	549 (19)
Total	58	17 357	2312 (13)

CIDI=Composite International Diagnostic Interview; CIS-R=Clinical Interview Schedule-Revised; DIS=Diagnostic Interview Schedule; DISH=Depression Interview and Structured Hamilton; MINI=Mini International Neuropsychiatric Interview; SCAN=Schedules for Clinical Assessment in Neuropsychiatry; SCID=Structured Clinical Interview for DSM Disorders.

Table 2 | Participant data by subgroup

Participant subgroup	Semistructured diagnostic interviews			Fully structured diagnostic interviews			Mini International Neuropsychiatric Interview		
	No of studies	No of participants	No (%) with major depression	No of studies	No of participants	No (%) with major depression	No of studies	No of participants	No (%) with major depression
All participants	29	6725	924 (14)	14	7680	839 (11)	15	2952	549 (19)
Participants not diagnosed as having or receiving treatment for mental health problem	20	2942	421 (14)	6	4161	306 (7)	6	927	168 (18)
Age <60 years	26	4132	629 (15)	14	5504	645 (12)	14	1958	310 (16)
Age ≥60 years	24	2577	295 (11)	10	2175	194 (9)	13	979	239 (24)
Women	28	3906	573 (15)	14	4285	463 (11)	15	1666	337 (20)
Men	25	2812	351 (12)	13	3395	376 (11)	15	1286	212 (16)
Very high country human development index	25	6195	739 (12)	9	5740	592 (10)	10	1924	430 (22)
High country human development index	4	530	185 (35)	2	326	61 (19)	3	542	61 (11)
Low-medium country human development index	–	–	–	3	1614	186 (12)	2	486	58 (12)
Non-medical care	2	567	105 (19)	2	963	74 (8)	2	299	72 (24)
Primary care	9	3163	377 (12)	5	3578	273 (8)	5	1290	168 (13)
Inpatient specialty care	8	867	121 (14)	2	372	34 (9)	1	137	25 (18)
Outpatient specialty care	12	2128	321 (15)	5	2767	458 (17)	7	1226	284 (23)

Some variables were coded at study level, and others were coded at participant level. Thus, number of studies does not always add up to total number in reference category.

unpublished studies, of 21 171 participants in 69 eligible published studies, 16 956 (80%) participants from 55 included published studies were included.

Of 58 included studies, 29 used semistructured reference standards, 14 used fully structured reference standards, and 15 used the MINI (table 1). The SCID was the most common semistructured interview (26 studies, total n=4733), and the CIDI was the most common fully structured interview (11 studies, total n=6272). Among studies that used semistructured, fully structured, and MINI diagnostic interviews, mean sample sizes were 232, 549, and 197, and mean numbers (percentages) with major depression were 32 (14%), 60 (11%), and 37 (19%), respectively (table 2).

PHQ-9 accuracy by reference standard

Table 3 and table 4 show comparisons of sensitivity and specificity estimates by reference standard category. A cut-off score of 10 maximized combined sensitivity and specificity among studies using semistructured interviews (sensitivity 0.88, 95% confidence interval 0.83 to 0.92; specificity 0.85, 0.82 to 0.88). Based on cut-off score 10, sensitivity and specificity were 0.70 (0.59 to 0.80) and 0.84 (0.77 to 0.89) for fully structured interviews and 0.77 (0.68 to 0.83) and 0.87 (0.83 to 0.90) for the MINI. Across cut-off scores, specificity estimates were similar across reference standards; however, sensitivity estimates for semistructured interviews were 5-22% higher than for fully structured interviews (median difference 18% at cut-off 10) and 2-15% higher than for the MINI (median difference 11% at cut-off 10). Receiver operating characteristic curves and area under the curve values are shown in supplementary figure B.

Heterogeneity analyses suggested moderate heterogeneity across studies, which improved in some

instances when we considered subgroups. Cut-off 10 sensitivity and specificity forest plots are shown in supplementary figure C, with τ^2 and R values shown in supplementary table C.

Figure 1 shows nomograms of positive and negative predictive values for cut-off score 10 for each reference standard category. For hypothetical values of major depression prevalence of 5-25%, estimates of positive predictive values based on summary sensitivity and specificity values ranged from 24% to 66% for semistructured interviews, 19% to 59% for fully structured interviews, and 24% to 66% for the MINI; estimates of negative predictive values ranged from 96% to 99% for semistructured interviews, 89% to 98% for fully structured interviews, and 92% to 99% for the MINI.

When examined with meta-regression analysis, consistent with our main results, we found that PHQ-9 sensitivity estimates for semistructured interviews were significantly higher than for fully structured interviews or the MINI (supplementary table D). The significant interactions corresponded to differences in sensitivity that across cut-off scores were 4-22% (median 18%) higher for semistructured interviews than for fully structured interviews and 1-16% (median 11%) higher for semistructured interviews than the MINI. Across all cut-off scores, the magnitude of the differences estimated on the basis of meta-regression were within 1% of those estimated using the original two stage bivariate random effects meta-analytic models.

PHQ-9 accuracy among participants not diagnosed as having or receiving treatment for mental health problem

Sensitivity and specificity estimates were not statistically significantly different for any reference

Table 3 | Comparison of sensitivity and specificity estimates among semistructured versus fully structured reference standards

Cut-off score	Semistructured reference standard*		Fully structured reference standard†		Difference across reference standards (semistructured minus fully structured)‡	
	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
5	0.98 (0.96 to 0.99)	0.55 (0.49 to 0.60)	0.93 (0.87 to 0.97)	0.54 (0.43 to 0.64)	0.05 (-0.01 to 0.13)	0.01 (-0.13 to 0.16)
6	0.98 (0.95 to 0.99)	0.63 (0.58 to 0.67)	0.91 (0.83 to 0.95)	0.61 (0.51 to 0.71)	0.07 (-0.01 to 0.18)	0.02 (-0.12 to 0.17)
7	0.98 (0.94 to 0.99)	0.69 (0.65 to 0.74)	0.86 (0.75 to 0.92)	0.69 (0.59 to 0.77)	0.12 (0.00 to 0.26)	0.00 (-0.10 to 0.15)
8	0.95 (0.91 to 0.97)	0.75 (0.71 to 0.79)	0.82 (0.71 to 0.89)	0.75 (0.66 to 0.82)	0.13 (0.00 to 0.28)	0.00 (-0.10 to 0.13)
9	0.91 (0.87 to 0.94)	0.80 (0.77 to 0.83)	0.74 (0.63 to 0.83)	0.79 (0.72 to 0.86)	0.17 (0.05 to 0.34)	0.01 (-0.08 to 0.12)
10	0.88 (0.83 to 0.92)	0.85 (0.82 to 0.88)	0.70 (0.59 to 0.80)	0.84 (0.77 to 0.89)	0.18 (0.04 to 0.36)	0.01 (-0.05 to 0.12)
11	0.84 (0.78 to 0.89)	0.89 (0.86 to 0.91)	0.62 (0.51 to 0.72)	0.87 (0.81 to 0.91)	0.22 (0.07 to 0.40)	0.02 (-0.04 to 0.10)
12	0.79 (0.73 to 0.83)	0.91 (0.89 to 0.93)	0.57 (0.45 to 0.68)	0.89 (0.85 to 0.93)	0.22 (0.05 to 0.40)	0.02 (-0.03 to 0.09)
13	0.70 (0.65 to 0.75)	0.93 (0.91 to 0.95)	0.49 (0.38 to 0.61)	0.92 (0.89 to 0.95)	0.21 (0.04 to 0.40)	0.01 (-0.03 to 0.07)
14	0.64 (0.58 to 0.70)	0.95 (0.93 to 0.96)	0.44 (0.32 to 0.56)	0.94 (0.91 to 0.96)	0.20 (0.03 to 0.40)	0.01 (-0.02 to 0.05)
15	0.56 (0.50 to 0.62)	0.96 (0.95 to 0.97)	0.35 (0.25 to 0.46)	0.96 (0.93 to 0.97)	0.21 (0.05 to 0.39)	0.00 (-0.02 to 0.04)

*Studies n=29; participants n=6725; major depression n=924.

†Studies n=14; participants n=7680; major depression n=839.

‡1 bootstrap iteration (0.01%) did not produce difference estimate for cut-off score 5. This iteration was removed before bootstrapped CI was determined.

Table 4 | Comparison of sensitivity and specificity estimates among semistructured versus MINI reference standards

Cut-off score	Semistructured reference standard*		MINI reference standard†		Difference across reference standards (semistructured minus MINI)	
	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
5	0.98 (0.96 to 0.99)	0.55 (0.49 to 0.60)	0.96 (0.93 to 0.98)	0.57 (0.50 to 0.64)	0.02 (-0.02 to 0.07)	-0.02 (-0.14 to 0.11)
6	0.98 (0.95 to 0.99)	0.63 (0.58 to 0.67)	0.93 (0.87 to 0.97)	0.66 (0.59 to 0.72)	0.05 (-0.01 to 0.12)	-0.03 (-0.13 to 0.09)
7	0.98 (0.94 to 0.99)	0.69 (0.65 to 0.74)	0.90 (0.82 to 0.94)	0.72 (0.66 to 0.78)	0.08 (-0.00 to 0.16)	-0.03 (-0.12 to 0.08)
8	0.95 (0.91 to 0.97)	0.75 (0.71 to 0.79)	0.86 (0.78 to 0.91)	0.78 (0.73 to 0.83)	0.09 (-0.01 to 0.19)	-0.03 (-0.11 to 0.06)
9	0.91 (0.87 to 0.94)	0.80 (0.77 to 0.83)	0.82 (0.72 to 0.88)	0.84 (0.79 to 0.87)	0.09 (-0.02 to 0.22)	-0.04 (-0.09 to 0.05)
10	0.88 (0.83 to 0.92)	0.85 (0.82 to 0.88)	0.77 (0.68 to 0.83)	0.87 (0.83 to 0.90)	0.11 (-0.01 to 0.25)	-0.02 (-0.07 to 0.06)
11	0.84 (0.78 to 0.89)	0.89 (0.86 to 0.91)	0.70 (0.62 to 0.77)	0.90 (0.86 to 0.92)	0.14 (0.01 to 0.30)	-0.01 (-0.06 to 0.05)
12	0.79 (0.73 to 0.83)	0.91 (0.89 to 0.93)	0.65 (0.56 to 0.72)	0.92 (0.89 to 0.94)	0.14 (-0.01 to 0.28)	-0.01 (-0.05 to 0.05)
13	0.70 (0.65 to 0.75)	0.93 (0.91 to 0.95)	0.57 (0.49 to 0.65)	0.94 (0.91 to 0.96)	0.13 (-0.03 to 0.26)	-0.01 (-0.04 to 0.04)
14‡	0.64 (0.58 to 0.70)	0.95 (0.93 to 0.96)	0.49 (0.42 to 0.56)	0.96 (0.93 to 0.97)	0.15 (0.01 to 0.28)	-0.01 (-0.04 to 0.03)
15‡	0.56 (0.50 to 0.62)	0.96 (0.95 to 0.97)	0.42 (0.35 to 0.49)	0.97 (0.95 to 0.98)	0.14 (-0.01 to 0.27)	-0.01 (-0.03 to 0.02)

MINI=Mini International Neuropsychiatric Interview.

*Studies n=29; participants n=6725; major depression n=924.

†Studies n=15; participants n=2952; major depression n=549.

‡For these cut-off scores, among studies that used MINI as reference standard, default optimizer in glmer failed, so bobyqa was used instead.

standard category when we restricted analyses to participants not currently diagnosed as having or receiving treatment for a mental health problem compared with all participants. See supplementary table E for results and supplementary figure D for receiver operating characteristic curves and area under the curve values.

PHQ-9 accuracy among subgroups

For each reference standard category, comparisons of sensitivity and specificity estimates based on bivariate models across PHQ-9 cut-off scores 5-15 among subgroups based on age, sex, country human development index, and participant recruitment setting are shown in supplementary table E, with forest plots shown in supplementary figure C, receiver operating characteristic curves and area under the curve values in supplementary figure D, and τ^2 and R values in supplementary table C.

Of the total of 484 categorical subgroup analyses that we did (22 subgroups \times 11 cut-off thresholds for sensitivity and specificity) using the bivariate model, four comparisons excluded the null value of zero difference for cut-off scores 5-15. No comparisons that were significantly different in one reference standard category were statistically significant in either of the

other two reference standard categories. Subgroup analyses are shown in supplementary table E.

In the meta-regression analyses, on the other hand, older age (measured continuously) was associated with higher specificity for all reference standards (supplementary table D). The significant interaction corresponded to specificity estimates that were 2-14% (median 6%) higher for participants aged 60 or over versus under 60 based on semistructured interviews, 2-14% (median 8%) higher based on fully structured interviews, and 1-8% (median 5%) higher based on the MINI (supplementary table D). Across all cut-off scores, the magnitudes of the differences estimated on the basis of meta-regression with dichotomous age were within 2% of those estimated using the original two stage bivariate random effects meta-analytic models.

Risk of bias sensitivity analyses

Supplementary table F shows Quality Assessment of Diagnostic Accuracy Studies-2 ratings for each included primary study, and comparisons of PHQ-9 accuracy across individual items for each reference standard category are shown in supplementary table E. For the item on blinding of the reference standard to PHQ-9 results, specificity was significantly greater for studies and participants with high or unclear risk




Fig 1 | Nomograms of positive (top) and negative (bottom) predictive values for cut-off score 10 of the Patient Health Questionnaire-9 (PHQ-9) for major depression prevalence values of 5-25% for each reference standard category (semistructured diagnostic interviews, fully structured diagnostic interviews, and Mini International Neuropsychiatric Interview (MINI))

versus low risk of bias for semistructured interviews but significantly greater for low risk versus high or unclear risk of bias for fully structured interviews and the MINI. For the item on recruiting a consecutive or random sample of participants, specificity was significantly greater for low risk versus high or unclear risk of bias for fully structured interviews and the MINI. We found no other statistically significant differences, and no significant differences were replicated across all reference standards.

Discussion

We compared the accuracy of scores on the PHQ-9 for screening to detect major depression, separately, with semistructured diagnostic interviews, fully structured diagnostic interviews (MINI excluded), and the MINI. Based on results from the semistructured interviews, which most closely replicate clinical interviews done by trained professionals, the PHQ-9 was more sensitive than has been reported in previous meta-analyses that combined reference standards.^{8 36} Specificity was similar to previous studies and across reference standards. Based on semistructured interviews, the standard cut-off score of 10 maximized combined sensitivity and specificity. We found evidence from multivariable meta-regression that the PHQ-9 may be more sensitive among older patients than younger patients, but this would not require that a different cut-off score be used. Results did not differ depending on whether studies that did not explicitly exclude patients already diagnosed as having depression were included

or excluded. Among studies conducted in primary care settings, approximately half of patients who screened positive on the PHQ-9 had major depression.

Findings in context

This is the first meta-analysis that has analyzed diagnostic accuracy for the PHQ-9 separately for different diagnostic interviews. Diagnostic interviews that are used to classify case status for major depression are imperfect reference standards. Semistructured interviews, such as the SCID,¹³ most closely approximate an expert diagnosis. They are set up to replicate a guided diagnostic conversation with standardized questions, with the option for interviewers to make additional queries and use clinical judgment to decide whether symptoms are present.^{16 17} Semistructured interviews involve lengthy processes that must be conducted by skilled diagnosticians and, thus, are expensive. Fully structured interviews, such as the CIDI,¹⁴ are designed to replicate as closely as possible expert administered semistructured interviews but are not expected to have the same level of validity and reliability. Fully structured interviews can be administered by lay interviewers and involve fully scripted standardized interview protocols that are read verbatim without additional probes or interpretation. Fully structured interviews are designed to increase reliability with administration by lay interviewers who are not trained to carry out diagnostic interviews independently at the possible cost of validity.^{16 17} The MINI is a specific fully structured interview that was designed to be administered in a fraction of the time compared with other interviews and described by its developers as intentionally overinclusive.^{19 20} Test-retest reliability for diagnosis of current major depression has been reported to be $\kappa=0.74$ for the SCID (n=51; mean 9 days)³⁷ and $\kappa=0.52$ for the CIDI (n=60; mean 2 days).³⁸

Consistent with the design features and rigor of each type of diagnostic interview, we previously reported that compared with semistructured interviews, fully structured interviews (excluding the MINI) classify more people with low symptoms as having major depression but fewer people with high symptoms.¹² We also found that the MINI identified approximately twice as many cases as other fully structured interviews.¹² The finding in this study that sensitivity was greater among studies with semistructured than fully structured reference standards is consistent with both the design features and rigor of the different types of diagnostic interviews and with our previous findings. The lower sensitivity among fully structured interviews may have been due to overdiagnosis of major depression among participants with low depressive symptom levels when fully structured interviews were used. In this meta-analysis, most participants (87%) did not have major depression, so misclassification of major depression among participants with subthreshold depressive symptom levels based on fully structured interviews might explain the lower sensitivity compared with semistructured interviews if the PHQ-9 were less

likely to identify “false positive” classifications based on fully structured interviews. The same logic would apply to the lower sensitivity for the MINI.

Among studies that used semistructured reference standards, sensitivity was also greater than reported in previous traditional meta-analyses, in which studies with semistructured and fully structured reference standards and the MINI were combined without adjustment. Using individual participant data from the 29 studies that used a semistructured interview as the reference standard, we found that at a cut-off score of 10, sensitivity and specificity were 0.88 and 0.85 compared with 0.78 and 0.87 in a 2015 conventional meta-analysis of 34 studies that combined reference standards.⁸ In primary care settings, we found sensitivity and specificity of 0.94 and 0.88 (nine studies with a semistructured interview) compared with 0.82 and 0.85 in a 2016 conventional meta-analysis of 20 studies that combined reference standards.³⁶

For semistructured interviews, prevalence of major depression in our dataset was 14%. Using our cut-off 10 accuracy estimates (sensitivity 0.88, specificity 0.85), the positive predictive value would be only 49%; thus 51% of all positive screens would be false positives. For primary care settings, where accuracy was even higher, prevalence of major depression was 12%. Using our accuracy estimates for cut-off 10 (sensitivity 0.94, specificity 0.88, positive predictive value 52%), 22% of patients in primary care would screen positive at this cut-off score, but only approximately half would be true positives.

To facilitate understanding for clinicians considering use of the PHQ-9 to screen for depression, we have developed a web based tool (depressionscreening100.com/phq). The tool can be used to estimate the expected number of positive screens and true and false screening outcomes based on results from this study.

Clinical implications

Screening for depression in primary care is recommended in the US,³⁹ but national guidelines from Canada and the UK advise against routine screening for depression.⁴⁰⁻⁴¹ Those guidelines cite the lack of evidence of benefit from well conducted randomized controlled trials, as well as concerns about high false positive rates, overdiagnosis, and substantial resource use and opportunity costs.⁴⁰⁻⁴¹ Well conducted and adequately powered trials designed specifically to assess the effects of depression screening are needed.¹²⁻⁴⁰⁻⁴³ If screening is to be done clinically on the basis of recommendations in the US, the cut-off score that maximizes sensitivity and specificity is the standard cut-off of 10 or greater. Whether using this standard cut-off score would maximize the likelihood that screening would successfully improve mental health and minimize unnecessary resource use and adverse outcomes if tested in a trial is, however, not known. Ideally, robust trials that are sufficiently powered to evaluate the effects of screening across a range of cut-off scores will be conducted. Clinical trials provide the best possible evidence to inform both the

decision on whether depression screening should be implemented as part of routine care and, if so, the thresholds for intervening or what steps might be taken for patients with borderline screening results.⁴⁴

Strengths and limitations of study

This was the first study to use individual participant data meta-analysis to assess diagnostic accuracy of the PHQ-9 or any other depression screening tool. Strengths include the large sample size, the ability to include results from all cut-off scores from all studies (rather than just those published), the ability to examine subgroups of participants, and the ability to assess accuracy separately across reference standards, which had not been done previously. Some limitations should also be considered. Firstly, we were unable to include primary data from 14 of 69 published eligible datasets (20% of eligible datasets and participants), and we restricted our analyses to those with complete data for all variables used in our various analyses (98% of available data). Nevertheless, for all cut-off scores other than 10, our sample was much larger than previous traditional meta-analyses of the PHQ-9. Secondly, despite the large sample size, substantial heterogeneity existed across studies, although it improved in some instances when we considered subgroups. We were not able to do subgroup analyses based on specific medical comorbidities or cultural aspects such as country or language, because comorbidity data were not available for more than half of participants and many countries and languages were represented in few primary studies. However, we were able to compare participant subgroups based on age, sex, country human development index, and participant recruitment setting category, which has not been done previously. Thirdly, although we categorized studies on the basis of the diagnostic interview administered, interviews are sometimes adapted and thus not always used in the way that they were originally designed. Although we coded for qualifications of interviewer for all semistructured interviews as part of our Quality Assessment of Diagnostic Accuracy Studies-2 rating, two studies used interviewers who did not meet typical standards, and approximately half of studies were rated as unclear on this item.

Although our original two stage bivariate random effects meta-analytic models did not find significant differences in accuracy estimates across participant subgroups, our meta-regressions suggested that specificity might be somewhat higher among older participants whether measured continuously or dichotomously. This difference in significance may be due to the differences between the analytical approaches. Whereas statistical significance of the interactions between covariates and accuracy estimates in the meta-regressions were based on parametric standard errors, statistical significance of subgroup comparisons in the two stage bivariate random effects models was based on non-parametric bootstrap methods. Moreover, whereas the meta-regression models provide a within study interpretation, the two

stage bivariate random effects models did not link study clusters across subgroups and thus focused more on between study comparisons.

Conclusions and policy implications

In summary, we found that the sensitivity of PHQ-9 compared with semistructured reference standards was substantially greater than when compared with fully structured reference standards or the MINI. It was also substantially higher than previously reported in conventional meta-analyses that combined reference standards.^{8 36} The standard cut-off score of 10 or greater maximized combined sensitivity and specificity. However, in primary care, approximately half of patients with positive screens would be false positives if this was used in practice, a concern that has been emphasized by the Canadian Task Force on Preventive Health Care, UK National Screening Committee, and UK National Institute for Health and Care Excellence, given the resources that would be needed for additional assessment and the possibility that some of these patients might be treated without benefit.^{40 41 43} Future research on the PHQ-9 should ideally be based on semistructured diagnostic interviews, should consider estimating probabilities of depression across the full spectrum of PHQ-9 screening scores (rather than dichotomizing scores at a cut-off), and should combine screening scores with individual characteristics to generate individualized probabilities of major depression.

Contributors: BLevis, AB, BDT, JB, PC, SG, JPAl, LAK, DM, SBP, IS, and RCZ were responsible for the study conception and design. JB and LAK designed and conducted database searches to identify eligible studies. BDT, DHA, BA, LA, HRB, MB, CHB, PB, GC, MHC, JCN, KC, YC, JMG, JD, JRF, FHF, DF, BG, FGS, CGG, BJH, JH, PAH, MHärter, UH, LH, SEH, MHudson, MI, KI, NJ, MEK, KMK, YK, SL, ML, SRL, BLöwe, LM, AM, SMS, TNM, KM, FLO, VP, BWP, PP, AP, KR, AGR, ISS, JS, ASidebottom, ASinning, LS, SCS, PLLT, AT, CMvdFC, HcVW, PAV, JW, MAW, KW, MY, and YZ contributed primary datasets that were included in this study. BLevis, KER, NS, MA, DBR, MJC, TAS, and BDT contributed to data extraction and coding for the meta-analysis. BLevis, AB, BDT and AWL contributed to the data analysis and interpretation. BLevis, AB, and BDT contributed to drafting the manuscript. All authors provided a critical review and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. AB and BDT are the guarantors. The affiliations of the members of the DEPRESSD Collaboration are given in the supplementary materials.

(DEPRESSD) Collaboration members: Dickens H Akena, Bruce Arroll, Liat Ayalon, Marleine Azar, Hamid R Baradaran, Murray Baron, Andrea Benedetti, Charles H Bombardier, Jill Boruff, Peter Butterworth, Gregory Carter, Marcos H Chagas, Juliana C N Chan, Matthew J Chiovitti, Kerrie Clover, Yeates Conwell, Pim Cuijpers, Janneke M de Man-van Ginkel, Jaime Delgado, Jesse R Fann, Felix H Fischer, Daniel Fung, Bizu Gelaye, Simon Gilbody, Felicity Goodyear-Smith, Catherine G Greeno, Brian J Hall, John Hambridge, Patricia A Harrison, Martin Härter, Ulrich Hegerl, Leanne Hides, Stevan E Hobfoll, Marie Hudson, Masatoshi Inagaki, John P A Ioannidis, Khalida Ismail, Nathalie Jetté, Mohammad E Khamseh, Kim M Kiely, Lorie A Kloda, Yunxin Kwan, Alexander W Levis, Brooke Levis, Shen-Ing Liu, Manote Lotrakul, Sonia R Loureiro, Bernd Löwe, Laura Marsh, Anthony McGuire, Dean McMillan, Sherina Mohd Sidik, Tiago N Munhoz, Kumiko Muramatsu, Flávia L Osório, Vikram Patel, Scott B Patten, Brian W Pence, Philippe Persoons, Angelo Picardi, Danielle B Rice, Kira E Riehm, Katrin Reuter, Alasdair G. Rooney, Nazanin Saadat, Tatiana A Sanchez, Iná S Santos, Juwita Shaaban, Abbey Sidebottom, Adam Simning, Ian Shrier, Lesley Stafford, Sharon C Sung, Pei Lin Lynnette Tan, Brett D Thombs, Alyna Turner, Christina M van der Feltz-Cornelis, Henk C van Weert, Paul A Vöhringer, Jennifer White, Mary A Whooley, Kirsty Winkley, Mitsuhiko Yamada, Roy C Ziegelstein, Yuying Zhang

Funding: This study was funded by the Canadian Institutes of Health Research (CIHR; KRS-134297). BLevis was supported by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship doctoral award. AB and BDT were supported by Fonds de recherche du Québec - Santé (FRQS) researcher salary awards. KER and NS were supported by CIHR Frederick Banting and Charles Best Canada Graduate Scholarship master's awards. AWL and MA were supported by FRQS Masters Training Awards. DBR was supported by a Vanier Canada Graduate Scholarship. Collection of data for the study by Arroll et al was supported by a project grant from the Health Research Council of New Zealand. Data collection for the study by Ayalon et al was supported from a grant from Lundbeck International. The primary study by Khamseh et al was supported by a grant (M-288) from Tehran University of Medical Sciences. The primary study by Bombardier et al was supported by the Department of Education, National Institute on Disability and Rehabilitation Research, Spinal Cord Injury Model Systems: University of Washington (grant No H133N060033), Baylor College of Medicine (grant No H133N060003), and University of Michigan (grant No H133N060032). PB was supported by Australian Research Council Future Fellowship FT130101444. Collection of data for the primary study by Zhang et al was supported by the European Foundation for Study of Diabetes, the Chinese Diabetes Society, Lilly Foundation, Asia Diabetes Foundation, and Liao Wun Yuk Diabetes Memorial Fund. YC received support from NIMH (R24MH071604) and the Centers for Disease Control and Prevention (R49 CE002093). Collection of data for the primary study by Delgado et al was supported by grant from St Anne's Community Services, Leeds, UK. Collection of data for the primary study by Fann et al was supported by grant RO1 HD39415 from the US National Center for Medical Rehabilitation Research. The primary studies by Amoozegar and by Fiest et al were funded by the Alberta Health Services, the University of Calgary Faculty of Medicine, and the Hotchkiss Brain Institute. The primary study by Fischer et al was funded by the German Federal Ministry of Education and Research (01GY1150). Data for the primary study by Gelaye et al was supported by grant from the NIH (T37 MD001449). Collection of data for the primary study by Gjerdingen et al was supported by grants from the NIMH (R34 MH072925, K02 MH65919, P30 DK50456). The primary study by Eack et al was funded by the NIMH (R24 MH56858). Collection of data for the primary study by Hobfoll et al was made possible in part by grants from NIMH (RO1 MH073687) and the Ohio Board of Regents. BJH received support from a grant awarded by the Research and Development Administration Office, University of Macau (MYRG2015-00109-FSS). Collection of data provided by MHärter and KR was supported by the Federal Ministry of Education and Research (grants No 01 GD 9802/4 and 01 GD 0101) and by the Federation of German Pension Insurance Institute. The primary study by Hides et al was funded by the Perpetual Trustees, Flora and Frank Leith Charitable Trust, Jack Brockhoff Foundation, Grosvenor Settlement, Sunshine Foundation, and Danks Trust. The primary study by Henkel et al was funded by the German Ministry of Research and Education. Data for the study by Razykov et al was collected by the Canadian Scleroderma Research Group, which was funded by the CIHR (FRN 83518), the Scleroderma Society of Canada, the Scleroderma Society of Ontario, the Scleroderma Society of Saskatchewan, Sclérodémie Québec, the Cure Scleroderma Foundation, Inova Diagnostics Inc, Euroimmun, FRQS, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. MHudson was supported by a FRQS Senior Investigator Award. Collection of data for the primary study by Hyphantis et al was supported by grant from the National Strategic Reference Framework, European Union, and the Greek Ministry of Education, Lifelong Learning and Religious Affairs (ARISTEIA-ABREVIATE, 1259). The primary study by Inagaki et al was supported by the Ministry of Health, Labour and Welfare, Japan. NJ was supported by a Canada Research Chair in Neurological Health Services Research. Collection of data for the primary study by Kiely et al was supported by National Health and Medical Research Council (grant No 1002160) and Safe Work Australia. KMK was supported by funding from a Australian National Health and Medical Research Council fellowship (grant No 1088313). The primary study by Lamers et al was funded by the Netherlands Organisation for Health Research and Development (grant No 945-03-047). The primary study by Liu et al was funded by a grant from the National Health Research Institute, Republic of China (NHRI-EX97-9706PI). The primary study by Lotrakul et al was supported by the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (grant No 49086). BLöwe received research grants from Pfizer, Germany, and from the medical faculty of the University of Heidelberg, Germany (project 121/2000) for the study by Gräfe et

al. The primary study by Mohd Sidik et al was funded under the Research University Grant Scheme from Universiti Putra Malaysia, Malaysia, and the Postgraduate Research Student Support Accounts of the University of Auckland, New Zealand. The primary study by Santos et al was funded by the National Program for Centers of Excellence (PRONEX/FAPERGS/CNPq, Brazil). The primary study by Muramatsu et al was supported by an educational grant from Pfizer US Pharmaceutical Inc. Collection of primary data for the study by BWP was provided by NIMH (R34MH084673). The primary studies by Osório et al were funded by Reitoria de Pesquisa da Universidade de São Paulo (grant No 09.1.01689.17.7) and Banco Santander (grant No 10.1.01232.17.9). FLO was supported by Productivity Grants (PQ-CNPq-2 number 301321/2016-7). The primary study by Picardi et al was supported by funds for current research from the Italian Ministry of Health. PP was supported by a grant from the Belgian Ministry of Public Health and Social Affairs and a restricted grant from Pfizer Belgium. JS was supported by funding from Universiti Sains Malaysia. The primary study by Rooney et al was funded by the UK National Health Service Lothian Neuro-Oncology Endowment Fund. The primary study by Sidebottom et al was funded by a grant from the United States Department of Health and Human Services, Health Resources and Services Administration (grant No R40MC07840). Simning et al's research was supported in part by grants from the NIH (T32 GM07356), Agency for Healthcare Research and Quality (R36 HS018246), NIMH (R24 MH071604), and the National Center for Research Resources (TL1 RR024135). LS received PhD scholarship funding from the University of Melbourne. Collection of data for the studies by Turner et al were funded by a bequest from Jennie Thomas through the Hunter Medical Research Institute. The study by van Steenberghe-Weijenburg et al was funded by Innovatiefonds Zorgverzekeraars. PAV was supported by the Fund for Innovation and Competitiveness of the Chilean Ministry of Economy, Development and Tourism, through the Millennium Scientific Initiative (grant No IS130005). Collection of data for the primary study by Williams et al was supported by an NIMH grant to LM (R01-MH069666). The primary study by Thombs et al was done with data from the Heart and Soul Study (PI Mary Whooley). The Heart and Soul Study was funded by the Department of Veterans Epidemiology Merit Review Program, the Department of Veterans Affairs Health Services Research and Development service, the National Heart Lung and Blood Institute (R01 HL079235), the American Federation for Ageing Research, the Robert Wood Johnson Foundation, and the Ischemia Research and Education Foundation. The primary study by Twist et al was funded by the UK National Institute for Health Research under its Programme Grants for Applied Research Programme (grant reference No RP-PG-0606-1142). The study by Wittkamp et al was funded by the Netherlands Organization for Health Research and Development (ZonMw) Mental Health Program (No 100.003.005 and 100.002.021) and the Academic Medical Center/University of Amsterdam. No other authors reported funding for primary studies or for their work on this study. No funder had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work other than that described above; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years with the following exceptions: NJ and SP received a grant, outside the submitted work, from the University of Calgary Hotchkiss Brain Institute, which was jointly funded by the Institute and Pfizer; Pfizer was the original sponsor of the development of the PHQ-9, which is now in the public domain; JCNC is a steering committee member or consultant of Astra Zeneca, Bayer, Lilly, MSD, and Pfizer and has received sponsorships and honorariums for giving lectures and providing consultancy, and her affiliated institution has received research grants from these companies; UH was an advisory board member for Lundbeck and Servier, a consultant for Bayer Pharma, and a speaker for Roche Pharma and Servier and has received personal fees from Janssen, all outside the submitted work; MI has received a grant from Novartis Pharma and personal fees from Meiji, Mochida, Takeda, Novartis, Yoshitomi, Pfizer, Eisai, Otsuka, MSD, Technomics, and Sumitomo Dainippon, all outside of the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: As this study involved secondary analysis of anonymized previously collected data, the Research Ethics Committee

of the Jewish General Hospital declared that this project did not need research ethics approval. However, for each included dataset, the authors confirmed that the original study received ethics approval and that all patients provided informed consent.

Transparency declaration: The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Data sharing: Requests to access data should be made to the corresponding author at brett.thombs@mcgill.ca.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

- 1 Thombs BD, Ziegelstein RC. Does depression screening improve depression outcomes in primary care? *BMJ* 2014;348:g1253. doi:10.1136/bmj.g1253
- 2 Thombs BD, Coyne JC, Cuijpers P, et al. Rethinking recommendations for screening for depression in primary care. *CMAJ* 2012;184:413-8. doi:10.1503/cmaj.111035
- 3 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606-13. doi:10.1046/j.1525-1497.2001.016009606.x
- 4 Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. *Psychiatr Ann* 2002;32:1-7. doi:10.3928/0048-5713-20020901-06
- 5 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. *JAMA* 1999;282:1737-44. doi:10.1001/jama.282.18.1737
- 6 Wittkamp KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the Patient Health Questionnaire: a systematic review. *Gen Hosp Psychiatry* 2007;29:388-95. doi:10.1016/j.genhosppsy.2007.06.004
- 7 Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med* 2007;22:1596-602. doi:10.1007/s11606-007-0333-y
- 8 Moriarty AS, Gilbody S, McMillan D, Manea L. Screening and case finding for major depressive disorder using the Patient Health Questionnaire (PHQ-9): a meta-analysis. *Gen Hosp Psychiatry* 2015;37:567-76. doi:10.1016/j.genhosppsy.2015.06.012
- 9 Levis B, Benedetti A, Levis AW, et al. Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A Comparison of Conventional and Individual-Patient-Data Meta-Analyses of the Patient Health Questionnaire-9 Depression Screening Tool. *Am J Epidemiol* 2017;185:954-64. doi:10.1093/aje/kww191
- 10 Thombs BD, Arthurs E, El-Baalbaki G, et al. Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review. *BMJ* 2011;343:d4825. doi:10.1136/bmj.d4825
- 11 Rice DB, Thombs BD. Risk of bias from inclusion of currently diagnosed or treated patients in studies of depression screening tool accuracy: A cross-sectional analysis of recently published primary studies and meta-analyses. *PLoS One* 2016;11:e0150067. doi:10.1371/journal.pone.0150067
- 12 Levis B, Benedetti A, Riehm KE, et al. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. *Br J Psychiatry* 2018;212:377-85. doi:10.1192/bjp.2018.54
- 13 First MB. *Structured clinical interview for the DSM (SCID)*. John Wiley & Sons, 1995.
- 14 Robins LN, Wing J, Wittchen HU, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry* 1988;45:1069-77. doi:10.1001/archpsyc.1988.01800360017003
- 15 Brugha TS, Jenkins R, Taub N, Meltzer H, Bebbington PE. A general population comparison of the Composite International Diagnostic Interview (CIDI) and the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). *Psychol Med* 2001;31:1001-13. doi:10.1017/S0033291701004184
- 16 Brugha TS, Bebbington PE, Jenkins R. A difference that matters: comparisons of structured and semi-structured psychiatric diagnostic

- interviews in the general population. *Psychol Med* 1999;29:1013-20. doi:10.1017/S0033291799008880
- 17 Nosen E, Woody SR. Diagnostic Assessment in Research. In: McKay D, ed. *Handbook of research methods in abnormal and clinical psychology*. Sage, 2008.
 - 18 Kurdyak PA, Gnam WH. Small signal, big noise: performance of the CIDI depression module. *Can J Psychiatry* 2005;50:851-6. doi:10.1177/070674370505001308
 - 19 Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. *Eur Psychiatry* 1997;12:224-31. doi:10.1016/S0924-9338(97)83296-8.
 - 20 Sheehan DV, Lecrubier Y, Sheehan KH, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. *Eur Psychiatry* 1997;12:232-41. doi:10.1016/S0924-9338(97)83297-X.
 - 21 Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;340:c221. doi:10.1136/bmj.c221
 - 22 Thoms BD, Benedetti A, Kloda LA, et al. The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. *Syst Rev* 2014;3:124. doi:10.1186/2046-4053-3-124
 - 23 McInnes MDF, Moher D, Thoms BD, et al, the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018;319:388-96. doi:10.1001/jama.2017.19163
 - 24 Stewart LA, Clarke M, Rovers M, et al, PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* 2015;313:1657-65. doi:10.1001/jama.2015.3656
 - 25 McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. *PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Explanation and Elaboration (PRESS E&E)*. CADTH, 2016.
 - 26 United Nations. Global Human Development Indicators. <http://hdr.undp.org/en/countries>.
 - 27 Whiting PF, Rutjes AW, Westwood ME, et al, QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-36. doi:10.7326/0003-4819-155-8-201110180-00009
 - 28 World Health Organization. *Schedules for clinical assessment in neuropsychiatry: manual*. Amer Psychiatric Pub Inc, 1994.
 - 29 Freedland KE, Skala JA, Carney RM, et al. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity. *Psychosom Med* 2002;64:897-905.
 - 30 Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. *Psychol Med* 1992;22:465-86. doi:10.1017/S0033291700030415
 - 31 Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. *Arch Gen Psychiatry* 1981;38:381-9. doi:10.1001/archpsyc.1981.01780290015001
 - 32 Riley RD, Dodd SR, Craig JV, Thompson JR, Williamson PR. Meta-analysis of diagnostic test studies using individual patient data and aggregate data. *Stat Med* 2008;27:6111-36. doi:10.1002/sim.3441
 - 33 van der Leeden R, Busing FM, Meijer E. *Bootstrap methods for two-level models. Technical Report PRM 97-04*. Leiden University, Department of Psychology, 1997.
 - 34 van der Leeden R, Meijer E, Busing FM. Resampling multilevel models. In: Leeuw J, Meijer E, eds. *Handbook of multilevel analysis*. Springer, 2008: 401-33. doi:10.1007/978-0-387-73186-5_11
 - 35 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58. doi:10.1002/sim.1186
 - 36 Mitchell AJ, Yadegarfar M, Gill J, Stubbs B. Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. *BJPsych Open* 2016;2:127-38. doi:10.1192/bjpo.bp.115.001685
 - 37 Shankman SA, Funkhouser CJ, Klein DN, Davila J, Lerner D, Hee D. Reliability and validity of severity dimensions of psychopathology assessed using the Structured Clinical Interview for DSM-5 (SCID). *Int J Methods Psychiatr Res* 2018;27:e1590. doi:10.1002/mpr.1590
 - 38 Semler G, Wittchen HU, Joschke K, et al. Test-retest reliability of a standardized psychiatric interview (DIS/CIDI). *Eur Arch Psychiatry Neural Sci* 1987;236:214-22. doi:10.1007/BF00383851
 - 39 Siu AL, Bibbins-Domingo K, Grossman DC, et al, US Preventive Services Task Force (USPSTF). Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA* 2016;315:380-7. doi:10.1001/jama.2015.18392
 - 40 Allaby M. *Screening for depression: A report for the UK National Screening Committee (Revised report)*. UK National Screening Committee, 2010.
 - 41 Joffres M, Jaramillo A, Dickinson J, et al, Canadian Task Force on Preventive Health Care. Recommendations on screening for depression in adults. *CMAJ* 2013;185:775-82. doi:10.1503/cmaj.130403
 - 42 Thoms BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on screening for depression in primary care: a systematic review. *BMC Med* 2014;12:13. doi:10.1186/1741-7015-12-13
 - 43 National Institute for Health and Care Excellence. Depression in adults: treatment and management. Consultation draft (May 2018). <https://www.nice.org.uk/guidance/gid-cgwave0725/documents/full-guideline-updated>
 - 44 Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. *BMJ* 2012;344:e686. doi:10.1136/bmj.e686

Supplementary materials